Filters
Our survey says … Building cyber resilience in the financial sector
Does regulation kill innovation?
How can GCs support growth and ensure regulatory compliance?
UPC patent infringement: recent updates for the life sciences sector
The United Patent Court (UPC) is increasingly influential in life sciences patent disputes, especially for pharmaceuticals, biotech, and medical devices. Handling 26% of infringement cases in this sector, the UPC offers faster, pan-European enforcement and is clarifying key legal issues. It’s becoming a crucial venue for protecting evolving life sciences innovations across Europe.
3 / 5 观点
Revocation of life sciences patents in the UPC
The Unified Patent Court (UPC), active since June 2023, is seeing strong uptake in pharma and biotech. Revocation decisions show a balanced 50:50 win rate for patentees and challengers. Key legal standards on novelty, obviousness, and inventive step are emerging, though some aspects remain unclear. Strategic use of the UPC offers broad enforcement, but revocation risks are higher for single-patent portfolios. Legal uncertainties, like the Bolar exemption, still need clarification.
4 / 5 观点
The UPC going beyond its borders: how your company can profit from the latest case law
The UPC now allows life sciences companies to enforce European patents more efficiently across multiple countries through its long-arm jurisdiction. This lets patent holders sue distributors based in UPC member states in a single action, even if products are sold or made in non-UPC countries. Following key rulings the UPC can issue cross-border injunctions covering several national patent parts, while respecting jurisdiction limits on patent validity challenges.
5 / 5 观点
.png?as=0&dmc=0&iar=0&thn=0&udi=0?as=0&h=182&iar=0&w=375&crop=1&hash=F2775BF2B93112F0E41CD43C8554BD3C)